Well it’s Ben a great week on the media thread. Looks like we are finally through the valley of death. We lost a few on that long painful journey. Quite a few. It wasn’t a trip for the faint hearted (Bedwetters) but those who kept a cool head and focussed on the prize shoukd have done very well loading up under .04 and as low as .031.
LC has showed us her cards this week. It’s a lay down misere. IMU is only going after cancers that have unmet needs. So we can run Registrational trials straight after ph1B. Only needing 10-20 patients worth of data.
This will cut times and cost by a big number. No ph 2 and 3 trials with hundreds of patients costing hundreds of millions. Another aspect that’s really important is biotechnology often gets superseded before it even gets through trials, Just like is happening over at RAC. It gets relegated to the dustbin before it ever gets to market.
So we’ll get a data cut soon so LC can triangulate the data and choose the best cancers to target. I’d expect 2 from Vaxinia and 1 from Oncarlytics.
5 Fast Track Registration Trials is a real valuable place to be. Raising capital to back them will be a stampede.
This will be a different beast in 6 months.
IMU Price at posting:
3.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)